Literature DB >> 11359439

T cell responses to highly active antiretroviral therapy defined by chemokine receptors expression, cytokine production, T cell receptor repertoire and anti-HIV T-lymphocyte activity.

A Giovannetti1, M Pierdominici, F Mazzetta, S Salemi, M Marziali, D Kuonen, F Iebba, E A Lusi, A Cossarizza, F Aiuti.   

Abstract

The immunological correlates of highly active antiretroviral therapy (HAART)-induced suppression of human immunodeficiency virus type 1 (HIV-1) replication have been investigated. 20 HIV-1-infected patients with mean CD4+ T cell count of 298/microl, plasma viral load of 4.7 log10 copies/ml and naive for protease inhibitors (PI) were studied during12 months of HAART. An increased number of both CD4+ and CD8+ naive T cells and a normalization of the frequency of CCR5- and CXCR4-expressing CD4+ T cells were readily observed after starting therapy. Single cell analysis of cytokine production after 12 months of HAART showed an increased number of interleukin (IL)-2-, but not IL-4- and (IFN)-gamma-, producing T cells and a decreased percentage of CD8+ IFN-gamma + cells. A correlation between the frequency of IFN-gamma-producing T cells and that of memory, CCR5+ and CD95+ T cells was demonstrated in both CD4+ and CD8+ subsets. The diversity of T cell receptor (TCR) variable beta (BV) chain repertoire significantly increased after 12 months of HAART within the CD4+ but not the CD8+ T cell subset. However, the level of perturbation of the third complementarity-determining region (CDR3), was not significantly modified by effective therapy. The number of anti-HIV Gag and Pol cytotoxic T lymphocytes precursors (CTLp) decreased during HAART and highly correlated with the CD8 IFN-gamma response. Ameliorated clinical conditions were observed in all patients in absence of any opportunistic infections during all the study period. These observations indicate that a better restoration of immunity may be obtained in patients starting HAART at less advanced stages of the disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11359439      PMCID: PMC1906033          DOI: 10.1046/j.1365-2249.2001.01502.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

1.  Caspase-dependent apoptosis of cells expressing the chemokine receptor CXCR4 is induced by cell membrane-associated human immunodeficiency virus type 1 envelope glycoprotein (gp120).

Authors:  M Biard-Piechaczyk; V Robert-Hebmann; V Richard; J Roland; R A Hipskind; C Devaux
Journal:  Virology       Date:  2000-03-15       Impact factor: 3.616

2.  CCR5 and CXCR4 chemokine receptor expression and beta-chemokine production during early T cell repopulation induced by highly active anti-retroviral therapy.

Authors:  A Giovannetti; F Ensoli; F Mazzetta; M De Cristofaro; M Pierdominici; D S Muratori; V Fiorelli; F Aiuti
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

3.  Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load.The RESTIM and COMET Study Groups.

Authors:  L Mollet; T S Li; A Samri; C Tournay; R Tubiana; V Calvez; P Debré; C Katlama; B Autran
Journal:  J Immunol       Date:  2000-08-01       Impact factor: 5.422

4.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy.

Authors:  G Dornadula; H Zhang; B VanUitert; J Stern; L Livornese; M J Ingerman; J Witek; R J Kedanis; J Natkin; J DeSimone; R J Pomerantz
Journal:  JAMA       Date:  1999-11-03       Impact factor: 56.272

5.  Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection.

Authors:  M D Hazenberg; S A Otto; J W Cohen Stuart; M C Verschuren; J C Borleffs; C A Boucher; R A Coutinho; J M Lange; T F Rinke de Wit; A Tsegaye; J J van Dongen; D Hamann; R J de Boer; F Miedema
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

6.  Factors influencing T-cell turnover in HIV-1-seropositive patients.

Authors:  J M McCune; M B Hanley; D Cesar; R Halvorsen; R Hoh; D Schmidt; E Wieder; S Deeks; S Siler; R Neese; M Hellerstein
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

7.  Human T cells with a type-2 cytokine profile are resistant to apoptosis induced by primary activation: consequences for immunopathogenesis.

Authors:  M Carbonari; T Tedesco; P Del Porto; R Paganelli; M Fiorilli
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

8.  Quantitation of antigen-specific immune responses in human immunodeficiency virus (HIV)-infected individuals by limiting dilution analysis.

Authors:  S Sabbaj; M F Para; R J Fass; P W Adams; C G Orosz; C C Whitacre
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

9.  Control of lymphocyte recirculation in man. II. Differential regulation of the cutaneous lymphocyte-associated antigen, a tissue-selective homing receptor for skin-homing T cells.

Authors:  L J Picker; J R Treer; B Ferguson-Darnell; P A Collins; P R Bergstresser; L W Terstappen
Journal:  J Immunol       Date:  1993-02-01       Impact factor: 5.422

10.  Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy.

Authors:  M E Sharkey; I Teo; T Greenough; N Sharova; K Luzuriaga; J L Sullivan; R P Bucy; L G Kostrikis; A Haase; C Veryard; R E Davaro; S H Cheeseman; J S Daly; C Bova; R T Ellison; B Mady; K K Lai; G Moyle; M Nelson; B Gazzard; S Shaunak; M Stevenson
Journal:  Nat Med       Date:  2000-01       Impact factor: 87.241

View more
  7 in total

1.  Decreases in plasma TNF-alpha level and IFN-gamma mRNA level in peripheral blood mononuclear cells (PBMC) and an increase in IL-2 mRNA level in PBMC are associated with effective highly active antiretroviral therapy in HIV-infected patients.

Authors:  P Brazille; N Dereuddre-Bosquet; C Leport; P Clayette; O Boyer; J-L Vildé; D Dormont; O Benveniste
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

Review 2.  Preserving HIV-specific T cell responses: does timing of antiretroviral therapy help?

Authors:  Bernard J C Macatangay; Charles R Rinaldo
Journal:  Curr Opin HIV AIDS       Date:  2015-01       Impact factor: 4.283

Review 3.  Harnessing CD8+ T Cells Under HIV Antiretroviral Therapy.

Authors:  Joanna A Warren; Genevieve Clutton; Nilu Goonetilleke
Journal:  Front Immunol       Date:  2019-02-26       Impact factor: 7.561

4.  Frequency of Effector Memory Cells Expressing Integrin α4β7 Is Associated With TGF-β1 Levels in Therapy Naïve HIV Infected Women With Low CD4+ T Cell Count.

Authors:  Nandini J Kasarpalkar; Shilpa Bhowmick; Vainav Patel; Lalita Savardekar; Sachee Agrawal; Jayanthi Shastri; Vikrant M Bhor
Journal:  Front Immunol       Date:  2021-03-22       Impact factor: 7.561

5.  Biased T-cell receptor repertoires in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).

Authors:  M Pierdominici; F Mazzetta; E Caprini; M Marziali; M C Digilio; B Marino; A Aiuti; F Amati; G Russo; G Novelli; F Pandolfi; G Luzi; A Giovannetti
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

6.  The number of CCR5 expressing CD4+ T lymphocytes is lower in HIV-infected long-term non-progressors with viral control compared to normal progressors: a cross-sectional study.

Authors:  Hinta Meijerink; Agnes R Indrati; Reinout van Crevel; Irma Joosten; Hans Koenen; Andre J A M van der Ven
Journal:  BMC Infect Dis       Date:  2014-12-13       Impact factor: 3.090

7.  Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors.

Authors:  Nora V Lieske; Kristian Tonby; Dag Kvale; Anne M Dyrhol-Riise; Kjetil Tasken
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.